Regresar

Survey of knowledge for diagnosing and managing pbkp_rediabetes in Latin-America: Cross-sectional study

Abstract:

Background: Pbkp_rediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of pbkp_rediabetes, little is known about the level of knowledge, beliefs and barriers to screening and treating pbkp_rediabetes amongst care health providers in Latin America. The aim of the present survey was to evaluate the knowledge and beliefs about pbkp_rediabetes amongst in Latin American health care providers. Methodology: In a cross-sectional study, we adapted the written survey designed by the Johns Hopkins University group, and applied it to health care providers across Latin America during three meetings, in 2017, and with physicians from primary care centers in Bucaramanga, Colombia convened in 2017. The survey consisted of questions under four headings, diabetes screening, management of pbkp_rediabetes, pharmacological treatment - metformin use, and demographic information. We perform a descriptive analysis to determine the differences in responses between different medical specialties. Results: The majority of the care providers that answered the survey were Colombian physicians, 54.5% of respondents had 10 years or more since completing their training and more women responded. Only 9.5% identified the 12 pbkp_rediabetes risk factors described in the literature. The most common risk factor identified was a family history of diabetes, followed by overweight, a sedentary lifestyle and dyslipidemia, while ethnicity was the risk factor least commonly. 47.1% answered that laboratory tests to detect pbkp_rediabetes are fasting glucose and HbA1C, 82.5% correctly identified fasting plasma glucose as the best test, 35.9% correctly responded that to the recommended weight loss goal is 5 to 7% and 49.1% that 150 min is considered the minimum level of physical activity per week. 78% agreed that the identification and treatment of pbkp_rediabetes is important. 56% believed that patients with pbkp_rediabetes progress more rapidly to diabetes and 40.6% considered that metformin could reduce the risk of diabetes in patients already diagnosed with pbkp_rediabetes. Conclusion: These results demonstrate that there are important gaps in the knowledge of the diagnosis, clinical implications and management of pbkp_rediabetes amongst Latin America health providers.